Functional Target Validation for Alzheimer's Disease-Related Dementias
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-NS-26-034
- Assistance listing (CFDA)
- 93.853
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions) are not allowed…
About this opportunity
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translat...
Related opportunities
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)National Institutes of Health
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)National Institutes of Health
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)National Institutes of Health
- Exposomic Contributions to ADRD Pathology and ResilienceNational Institutes of Health
- Research Project Cooperative Agreements in Aging and/or Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) ResearchNational Institutes of Health
- Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)National Institutes of HealthCloses May 2028Up to $1.0M